Management of early stage chronic myeloid leukemia: state-of-the-art approach and future perspectives.


Tyrosin kinase inhibitors (TKI), have dramatically changed the natural history of chronic myeloid leukemia (CML) leading to an impressive increase in overall survival rates and allowing many CML patients to achieve a close-to-normal life expectancy. Unfortunately, there is growing evidence that these drugs are not curative, about 30-35% of the patients who… (More)


  • Presentations referencing similar topics